hCD3EDG/hCD19(BALB/c)

Nomenclature

BALB/cAnSmoc-Cd19tm(hCD19)Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Smoc

Cat. NO.

NM-XA-240066

Strain State

Repository Live

Export PDF

Model Description

The hCD3EDG(BALB/c)(NM-HU-220122) was crossed with hCD19(BALB/c)(NM-HU-220606) to generate hCD19(BALB/c)/hCD3EDG(BALB/c) mice.

Validation Data

image.png

Fig.1 Detection of immune phenotype in WT BALB/c and HO/HO hCD3EDG/hCD19 mice.(male, n=3)

image.png

Fig.2 Detection of phenotype in Peripheral blood in WT BALB/c and HO/HO hCD3EDG/hCD19 mice.

image.png

Fig.3 Detection of phenotype in Spleen in WT BALB/c and HO/HO hCD3EDG/hCD19 mice.

image.png

Fig.4 Detection of phenotype in Lymph node in WT BALB/c and HO/HO hCD3EDG/hCD19 mice.

image.png

Fig.5 Blinatumomab injections were repeated daily for 5 days and immune cells in the PB of mice after therapy were measured by flow cytometry(n=6). Average ± SEM;*P<0.05,**P<0.01,***P<0.001;(Student' s t test)

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more